Almirall S.A. Logo

Almirall S.A.

Global biopharmaceutical company specializing in medical dermatology and skin health.

ALM | MC

Overview

Corporate Details

ISIN(s):
ES0157097017
LEI:
95980020140005007996
Country:
Spain
Address:
Ronda General Mitre 151, 08022 Barcelona

Description

Almirall S.A. is a global biopharmaceutical company specializing in medical dermatology. The company focuses on the research, development, manufacturing, and commercialization of proprietary medicines to address significant unmet needs in skin health. Leveraging scientific innovation, Almirall provides medical solutions designed to improve the well-being and quality of life for patients. Its operations encompass in-house research and development, strategic partnerships, and in-licensing to expand its portfolio of dermatological treatments.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-17 18:19
Almirall ha procedido al cierre y desembolso de su emisión de obligaciones simp…
Spanish 184.0 KB
2025-05-12 07:33
Información sobre el calendario del dividendo
Spanish 104.4 KB
2025-05-12 07:23
Información sobre dividendos
Spanish 188.2 KB
2025-05-12 07:15
Acuerdos adoptados por el Consejo de Administración
Spanish 105.9 KB
2025-05-12 07:04
Acuerdos adoptados por la Junta General de Accionistas 2025
Spanish 182.9 KB
2025-05-12 06:57
Almirall remite presentación sobre los resultados del primer trimestre de 2025 …
Spanish 1.3 MB
2025-05-12 06:51
Almirall realizará una presentación vía webcast para explicar los Resultados de…
Spanish 101.3 KB
2025-05-12 00:00
Acuerdos adoptados por la Junta General de Accionistas 2025
Spanish 182.9 KB
2025-04-09 11:58
Operaciones del contrato de liquidez durante el primer trimestre de 2025
English 187.4 KB
2025-04-01 13:17
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad 2025 -…
Spanish 279.9 KB
2025-04-01 00:00
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad 2025 -…
Spanish 279.9 KB
2025-03-31 17:58
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad 2025
Spanish 141.0 KB
2025-03-31 00:00
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad 2025
Spanish 141.0 KB
2025-03-06 07:28
Almirall anuncia el plan de transición del CFO
Spanish 72.6 KB
2025-02-24 06:43
La sociedad remite presentación sobre los resultados del ejercicio 2024
Spanish 1.3 MB

Automate Your Workflow. Get a real-time feed of all Almirall S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Almirall S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Almirall S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celltrion Pharm Inc. Logo
Manufactures and supplies chemical pharmaceuticals and biosimilar products.
South Korea
068760
Develops and manufactures medical devices, tissue grafts, and advanced biologics.
South Korea
049180
Celon Pharma S.A. Logo
An integrated pharmaceutical company researching and manufacturing modern drugs.
Poland
CLN
Celularity Inc Logo
Develops allogeneic cell therapies and biomaterials from the human placenta.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Clinical-stage pharmaceutical company developing medicines for unmet medical needs.
United States of America
CNTA
Century Therapeutics, Inc. Logo
Develops iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases.
United States of America
IPSC
Cereno Scientific AB Logo
Clinical-stage biotech developing drugs for rare cardiovascular & pulmonary diseases.
Sweden
CRNO
CERO THERAPEUTICS HOLDINGS, INC. Logo
Immunotherapy company developing engineered T cell therapeutics for cancer treatment.
United States of America
CERO
CERUS CORP Logo
Develops pathogen inactivation technology to reduce transfusion-transmitted infections.
United States of America
CERS
Cessatech A/S Logo
A biotech company developing medicines for children's acute pain management.
Denmark
CESSA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.